Table 4.
Summary of Participants With Postbaseline Bilirubin >2 × Upper Limit of Normal Elevations
| Hepatic | ALT (U/mL) | Total Bilirubin (μmol/L) | ||||||
|---|---|---|---|---|---|---|---|---|
| Impairment Group | Viral Hepatitis History? | Concomitant Medications During the Study | Baseline | Day 29 | Day 57 | Baseline | Day 29 | Day 57 |
| Moderate | Yes | Human insulin 70‐76 U bid | 24 | 53 | 23 | 38 | 41 | 46 |
| Human insulin 8 U prn | ||||||||
| Furosemide 60 mg bid | ||||||||
| Omeprazole 20 mg/day | ||||||||
| Propranolol 20 mg tid | ||||||||
| Spironolactone 100 mg bid | ||||||||
| Diphenhydramine 25 mg prn | ||||||||
| Trazodone 50 mg prn | ||||||||
| Cephalexin 500 mg qid | ||||||||
| Moderate | No | Amiloride 5 mg (1 dose) | 56 | 48 | 48 | 29 | 51 | 22 |
| Furosemide 20 mg (1 dose) | ||||||||
| Human insulin 12 U bid | ||||||||
| Pregabalin 75 mg (1 dose) | ||||||||
| Moderate | No | None | 38 | 35 | 50 | 45 | 14 | 50 |
ALT, alanine transaminase; bid, twice daily; tid, 3 times daily; prn, as required; qid, 4 times daily.